How should osteopenia be treated based on FRAX (Fracture Risk Assessment Tool) results?

Treatment of Osteopenia Based on FRAX

Pharmacologic therapy is strongly recommended for patients with osteopenia (T-score between -1.0 and -2.5) when FRAX shows 10-year major osteoporotic fracture risk ≥20% OR hip fracture risk ≥3% in the U.S. 1

Risk Stratification Algorithm

The treatment decision for osteopenia hinges on calculating fracture risk using FRAX and applying specific thresholds:

Step 1: Calculate FRAX Score

• Use the FRAX calculator (with BMD when available) to determine 10-year fracture probability 1
• FRAX with BMD is more accurate than without BMD - improves predictive accuracy for both major osteoporotic fractures (MOF) and hip fractures 2
• For glucocorticoid users taking >7.5 mg/day: multiply MOF risk by 1.15 and hip fracture risk by 1.2 3, 4

Step 2: Apply Treatment Thresholds

Initiate pharmacologic therapy if ANY of the following:

• FRAX 10-year MOF risk ≥20% 1
• FRAX 10-year hip fracture risk ≥3% 1
• History of fragility fracture of hip or spine (even with osteopenia) 1

Consider treatment for moderate risk:

• FRAX 10-year MOF risk 10-19% OR hip fracture risk >1% but <3% 3, 4

Defer treatment for low risk:

• FRAX 10-year MOF risk <10% AND hip fracture risk <1% 5

Pharmacologic Treatment Options

First-Line Agents (High Fracture Risk)

Oral bisphosphonates are strongly recommended as initial therapy for most patients with osteopenia meeting treatment thresholds 1:

• Alendronate (70 mg weekly)
• Risedronate (35 mg weekly or 150 mg monthly)
• Zoledronic acid (5 mg IV annually) - alternative for those unable to tolerate oral therapy

These agents have proven efficacy in reducing hip, vertebral, and nonvertebral fractures 1.

Very High-Risk Patients

Consider anabolic agents first if FRAX shows MOF >30% or hip fracture >4.5% 1:

• Teriparatide, abaloparatide, or romosozumab followed by antiresorptive therapy 1
• Denosumab (60 mg subcutaneous every 6 months) is also appropriate 1

Special Populations

For glucocorticoid-induced osteoporosis with osteopenia, treatment thresholds are lower and bisphosphonates are strongly recommended even at moderate risk 3, 4.

Non-Pharmacologic Interventions (Universal)

All patients with osteopenia require lifestyle modifications regardless of FRAX score 1:

• Calcium: 1200 mg daily (dietary plus supplemental)
• Vitamin D: 800-1000 IU daily
• Weight-bearing and resistance exercises (Grade A recommendation) 1
• Fall risk reduction counseling, especially for elderly 1
• Smoking cessation 1
• Limit alcohol to ≤2 units/day 6
• Consider physical therapy referral to reduce fall risk and improve quality of life 1

Monitoring

• Repeat DXA every 1-2 years during treatment until stable, then less frequently 1
• Use same facility and DXA machine when possible 1
• Monitor for treatment adherence and efficacy 1

Critical Pitfalls to Avoid

1. Don't ignore osteopenia with high FRAX scores - these patients have fracture risk equivalent to osteoporosis and require treatment 1
2. Don't treat all osteopenia - only 34-40% of osteopenic patients meet high-risk FRAX thresholds requiring treatment 7
3. Always include BMD in FRAX when available - significantly improves predictive accuracy 2
4. For glucocorticoid users, adjust FRAX upward if dose >7.5 mg/day 3, 4
5. Prior fragility fracture trumps FRAX - automatically qualifies for treatment even with normal FRAX 1

Evidence Quality Note

The 2020 AACE/ACE guidelines provide the most comprehensive and recent framework for osteopenia treatment based on FRAX 1. The recommendation for treating osteopenia at FRAX thresholds of ≥20% MOF or ≥3% hip fracture is Grade A (highest quality evidence). This approach has been validated by screening trials showing significant fracture reduction when treatment is targeted to high-risk individuals identified by FRAX 2.

The key principle: osteopenia is a densitometric diagnosis, but treatment decisions must be based on absolute fracture risk, not T-score alone.